HIV/AIDS: History and Discovery

The story of HIV/AIDS spans little more than four decades, yet it has reshaped medicine, science, and society. It begins with an alarm sounded on 5 June 1981, when the U.S. Centers for Disease Control and Prevention reported a cluster of a rare pneumonia in five young men in Los Angeles. Within two years, scientists in Paris had isolated the virus responsible; within five, the world had agreed to call it HIV; and within fifteen, combination therapy had turned a near-certain death sentence into a manageable chronic condition. This page traces that history honestly — the science, the people, the famous priority dispute over who discovered the virus, and the communities who lived, suffered, organized, and ultimately changed the course of the epidemic. It is written with respect for everyone affected and without stigma.

Table of Contents

  1. The First Alarm: June 1981
  2. A Frightening New Syndrome Gets a Name
  3. Paris, 1983: The Virus Is Isolated
  4. The Gallo–Montagnier Priority Dispute
  5. From LAV and HTLV-III to "HIV" (1986)
  6. The First Drugs: AZT and the Long Road to HAART
  7. Where HIV Came From: A Zoonotic Origin
  8. Activism, the Nobel Prize, and a Changed World
  9. Research Papers and References
  10. Connections

The First Alarm: June 1981

The recognized history of AIDS opens on 5 June 1981. On that date the CDC's Morbidity and Mortality Weekly Report (MMWR) carried a brief, now-famous notice describing five previously healthy young men in Los Angeles — all of them gay — who had developed Pneumocystis carinii pneumonia (PCP, the organism is now classified as Pneumocystis jirovecii). PCP was an opportunistic infection seen almost exclusively in people whose immune systems had collapsed; finding it in young, otherwise healthy men was deeply abnormal. The cases had been recognized and reported by Los Angeles immunologist Dr. Michael Gottlieb and colleagues, working with CDC officials, after Gottlieb noticed a striking depletion of CD4 helper T-cells in the patients.

Within weeks the picture darkened. On 3 July 1981 the MMWR and the lay press reported clusters of Kaposi's sarcoma — a rare, normally indolent skin cancer — appearing aggressively in young gay men in New York City and California, often alongside the same opportunistic infections. Two rare conditions, a "pneumonia" and a "cancer," were striking the same population at the same time. Something was destroying these patients' cellular immunity, and no one yet knew what. By the end of 1981 the CDC had logged hundreds of cases and a frightening death toll, and clinicians in New York, San Francisco, and Los Angeles understood they were facing an entirely new disease.

Back to Table of Contents

A Frightening New Syndrome Gets a Name

For its first year the new illness had no settled name, and several of the early labels caused lasting harm. Because the first recognized clusters were among gay men, the condition was informally and stigmatizingly called GRID — "gay-related immune deficiency" — and in the press, cruelly, the "gay plague." These names were quickly shown to be wrong as well as damaging: by late 1981 and 1982 the same immune collapse was being identified in people with hemophilia who received clotting-factor concentrates, in recipients of blood transfusions, in people who injected drugs, and in infants — making clear that the cause was a transmissible agent in blood and bodily fluids, not anything intrinsic to one community.

In 1982 the CDC adopted the name "acquired immune deficiency syndrome," or AIDS, defining it as a syndrome of opportunistic infections and cancers arising from an unexplained, acquired defect in cell-mediated immunity. The new name was deliberately neutral and descriptive. It is important to state plainly, because it was not always understood at the time: AIDS was never a "lifestyle" disease or a moral judgment. It is the late stage of infection with a specific virus that can affect anyone, and the early stigma attached to it deepened suffering and slowed the public-health response. Honesty about that history is part of honoring the people who lived through it.

Back to Table of Contents

Paris, 1983: The Virus Is Isolated

The decisive scientific breakthrough came in 1983 at the Pasteur Institute in Paris. A team that included the young virologist Françoise Barré-Sinoussi, working with Jean-Claude Chermann and under the direction of Luc Montagnier, examined a lymph-node biopsy taken from a patient with persistent swollen glands — an early sign that often preceded AIDS. In that culture they detected the activity of reverse transcriptase, the signature enzyme of a retrovirus, and observed retroviral particles budding from infected cells. They had isolated a new human retrovirus.

The Pasteur team named their isolate LAV — lymphadenopathy-associated virus — and published their findings in the journal Science on 20 May 1983, in a paper titled "Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)." Crucially, they recognized that this virus was distinct from the human T-cell leukemia viruses (HTLV-I and HTLV-II) already described by other laboratories. The 1983 Science paper is one of the most consequential publications in modern medicine: it is the first report of the virus the world would come to know as HIV. It did not yet prove that this virus caused AIDS — establishing causation took further work over the following year — but it correctly identified the agent.

Back to Table of Contents

The Gallo–Montagnier Priority Dispute

What followed became one of the most famous priority disputes in the history of science, and it deserves to be told carefully and fairly. In the United States, the laboratory of Dr. Robert Gallo at the National Cancer Institute (NIH) — Gallo was already renowned for co-discovering the first human retroviruses, HTLV-I and HTLV-II — was pursuing the same quarry. In 1984 Gallo's group published a series of papers in Science reporting a retrovirus they called HTLV-III, demonstrating that it could be grown continuously in cultured cell lines, showing convincingly that it was the cause of AIDS, and — of enormous practical importance — developing a blood test to detect antibodies to the virus. That test, licensed in 1985, allowed the blood supply to be screened and is one of the era's great public-health achievements.

The conflict arose because LAV (Pasteur) and HTLV-III (NIH) turned out to be the same virus — in fact genetically almost identical — and the Pasteur team had sent samples of their LAV isolate to Gallo's laboratory in 1983, before Gallo's 1984 publications. A bitter, years-long dispute over scientific credit and over lucrative patent rights to the blood test ensued, involving the two governments at the highest levels. It was partly settled in 1987 by an extraordinary agreement brokered by U.S. President Ronald Reagan and French Prime Minister Jacques Chirac, which split the blood-test patent royalties and officially credited the two teams as co-discoverers. Later genetic analyses indicated that Gallo's HTLV-III had most likely originated, through inadvertent cross-contamination in the laboratory, from the very LAV sample sent from Paris. The honest summary accepted by most historians and by the Nobel committee is this: the Pasteur team isolated the virus first; Gallo's laboratory provided much of the definitive proof that it causes AIDS and produced the first widely used blood test. Both contributions were indispensable.

Back to Table of Contents

From LAV and HTLV-III to "HIV" (1986)

By the mid-1980s the same virus was circulating in the literature under at least three names — the Pasteur group's LAV, Gallo's HTLV-III, and a third isolate from California called ARV (AIDS-associated retrovirus). This was confusing and, given the ongoing dispute, politically charged. To resolve it, a subcommittee of the International Committee on the Taxonomy of Viruses (ICTV), chaired by virologist Harold Varmus, proposed a single neutral name. In 1986 the committee announced its choice: human immunodeficiency virus, abbreviated HIV. The new name described what the virus does — it is a human virus that causes immune deficiency — without favoring any laboratory's original label.

Two further pieces of nomenclature followed. A second, related virus found chiefly in West Africa, somewhat less easily transmitted and slower to progress, was characterized and named HIV-2; the original pandemic virus became HIV-1. The standardized naming mattered for more than tidiness: a common vocabulary let researchers worldwide compare results, build diagnostics, and coordinate the global response to a disease that, by the late 1980s, had been recognized on every inhabited continent.

Back to Table of Contents

The First Drugs: AZT and the Long Road to HAART

Identifying the virus was only the beginning; the harder task was treating it. The first breakthrough drug had an unlikely history. AZT (zidovudine) had been synthesized back in 1964 as a candidate cancer therapy, failed in that role, and sat unused for two decades. In the mid-1980s it was pulled from the shelf, found to block HIV's reverse transcriptase in the laboratory, rushed through trials, and in March 1987 became the first drug approved by the U.S. FDA to treat HIV/AIDS. AZT was a genuine milestone and offered real, if modest and temporary, benefit — but it was extraordinarily expensive, carried serious side effects such as anemia, and, used alone, the virus rapidly evolved resistance to it. The arrival of AZT also coincided with fierce activism (discussed below) demanding faster, fairer access to experimental drugs.

The transformative advance came almost a decade later. Researchers learned to combine drugs from different classes — nucleoside reverse-transcriptase inhibitors like AZT together with the newly developed protease inhibitors and other agents — into three-drug regimens. In 1996 this approach, called combination antiretroviral therapy or HAART (highly active antiretroviral therapy), was shown to suppress the virus durably to very low levels while raising a high genetic barrier to resistance. The effect was so dramatic that clinicians spoke of a "Lazarus effect" as gravely ill patients recovered. HAART did not cure HIV, but it converted it, for those who could obtain and tolerate treatment, from a fatal disease into a manageable chronic condition compatible with a near-normal lifespan. Later science added the equally important public-health insight captured in the phrase Undetectable = Untransmittable (U=U): a person on effective treatment with an undetectable viral load does not transmit HIV sexually. Modern medicine also offers pre-exposure prophylaxis (PrEP) to prevent infection — advances built directly on the discoveries chronicled here.

Back to Table of Contents

Where HIV Came From: A Zoonotic Origin

Where did HIV come from in the first place? The well-supported scientific answer is that HIV is a zoonosis — a virus that crossed from animals into humans. HIV-1, the virus responsible for the global pandemic, is closely related to simian immunodeficiency virus (SIV) found in chimpanzees (specifically SIVcpz in the subspecies Pan troglodytes troglodytes of west-central Africa). The most likely route of cross-species transmission was contact with infected blood during the hunting and butchering of chimpanzees for bushmeat — a hunter with a cut hand exposed to chimpanzee blood is the classic scenario. HIV-2, the West African virus, similarly derives from SIV in sooty mangabey monkeys. These conclusions rest on genetic comparison of human and primate viruses and are well established; the precise details continue to be refined by ongoing research.

When did this happen? Molecular-clock studies — which estimate a virus's age from the rate at which its genome accumulates mutations — trace the most recent common ancestor of the main pandemic lineage (HIV-1 group M) to roughly 1920, in or near Kinshasa in what is now the Democratic Republic of the Congo. A widely cited 2014 analysis argued that a combination of a growing colonial city, railways and river transport, and social changes allowed a local infection to ignite into a regional and then global epidemic over the following decades, largely unseen, until it surfaced in the United States and Europe in 1981. It bears emphasizing that this reconstruction, while strongly evidence-based, is a scientific hypothesis built on phylogenetic dating, not an eyewitness record; the estimated dates carry a margin of uncertainty (the common ancestor is placed with about 95% confidence between roughly 1909 and 1930). What is not in serious scientific doubt is the broad picture: a chimpanzee virus crossed into humans in early-twentieth-century Central Africa and, decades later, became one of the defining pandemics of the modern era.

Back to Table of Contents

Activism, the Nobel Prize, and a Changed World

The history of HIV/AIDS cannot honestly be told as science alone, because the people most affected were not passive patients — they were activists, advocates, and partners in the research itself. As the epidemic devastated gay communities through the 1980s amid stigma, fear, and slow official response, organizations such as ACT UP (the AIDS Coalition to Unleash Power), founded in 1987, and groups like the Gay Men's Health Crisis transformed the relationship between patients and medicine. They demanded faster drug approvals, lower prices, compassionate access to experimental therapies, honest public-health education, and a seat at the table in designing clinical trials. Their pressure permanently reshaped how the FDA evaluates drugs for life-threatening diseases and how researchers involve affected communities — a legacy that now benefits patients with many other conditions. The NAMES Project AIDS Memorial Quilt, begun in 1987, became an enduring monument to the individual human beings — hundreds of thousands of them — lost to the disease.

The scientific story reached a formal milestone in 2008, when the Nobel Prize in Physiology or Medicine was awarded to Françoise Barré-Sinoussi and Luc Montagnier "for their discovery of human immunodeficiency virus," sharing the prize with Harald zur Hausen, who was honored separately for linking human papillomavirus to cervical cancer. The award settled the priority question in the eyes of the Nobel committee by recognizing the Pasteur team's 1983 isolation; its omission of Robert Gallo was widely noted and debated, given his pivotal role in proving causation and building the blood test. Today, more than four decades after that first MMWR notice, HIV remains incurable, but it is preventable and, with treatment, survivable: tens of millions of people live with HIV worldwide, and effective antiretroviral therapy has saved many millions of lives. The arc from June 1981 to the present — from a baffling cluster of pneumonia to a once-daily pill — stands as one of the fastest and most consequential campaigns in the history of medicine, achieved by scientists and affected communities together.

Back to Table of Contents

Research Papers and References

The references below combine the landmark peer-reviewed publications that define this history — the 1983 Science isolation paper, the 2008 Nobel announcement, and the 2014 origins study — with curated PubMed topic-search links into the broader literature. Real DOIs and PMIDs are given where they could be confirmed; the remaining entries open at PubMed (U.S. National Library of Medicine) in a new tab. Historical CDC MMWR notices are named in the article as primary public-health sources.

  1. Barré-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science. 1983;220(4599):868-871. — doi:10.1126/science.6189183
  2. Faria NR, Rambaut A, Suchard MA, et al. The early spread and epidemic ignition of HIV-1 in human populations. Science. 2014;346(6205):56-61. — doi:10.1126/science.1256739
  3. Cohen J. The 2008 Nobel Prize in Physiology or Medicine — HIV and HPV discoveries honored. (Nobel announcement coverage) — PubMed: 2008 Nobel Prize for the discovery of HIV
  4. Gallo RC, Montagnier L. The discovery of HIV as the cause of AIDS. New England Journal of Medicine. 2003;349(24):2283-2285. — doi:10.1056/NEJMp038194
  5. Centers for Disease Control. Pneumocystis pneumonia — Los Angeles. MMWR. 1981;30(21):250-252. (The first recognized report of AIDS, 5 June 1981.) — CDC MMWR — 5 June 1981
  6. Sharp PM, Hahn BH. Origins of HIV and the AIDS pandemic. Cold Spring Harbor Perspectives in Medicine. 2011;1(1):a006841. — doi:10.1101/cshperspect.a006841
  7. Keele BF, Van Heuverswyn F, Li Y, et al. Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science. 2006;313(5786):523-526. — doi:10.1126/science.1126531
  8. History of zidovudine (AZT), the first approved HIV drug (1987) — PubMed: zidovudine (AZT) history and first approval
  9. Combination antiretroviral therapy (HAART) and durable viral suppression, 1996 — PubMed: HAART and the transformation of HIV care
  10. Naming of the human immunodeficiency virus (HIV), 1986 — PubMed: the 1986 naming of HIV
  11. The Gallo–Montagnier priority dispute and the LAV/HTLV-III controversy — PubMed: the LAV / HTLV-III priority dispute
  12. Kaposi's sarcoma and the early clinical recognition of AIDS, 1981 — PubMed: Kaposi's sarcoma and early AIDS
  13. ACT UP, AIDS activism, and the reform of drug approval — PubMed: AIDS activism and drug-approval reform
  14. HIV-2, sooty mangabeys, and the West African epidemic — PubMed: HIV-2 origin in sooty mangabeys

External Authoritative Resources

Back to Table of Contents

Connections

Back to Table of Contents